Genespire to take rare disease gene therapy to clinic in 2026
Rare disease biotech Genespire is looking to take its single-dose gene therapy – GENE202 – to the clinic in 2026, …
Post
-
-
IntraBio’s ataxia-telangiectasia drug meets endpoints in pivotal trial
IntraBio will head to regulators after its neurological rare disease drug met primary and secondary endpoints in a Phase III …
-
Free webinar: Ensuring compliance-first logistics for reliable clinical trials
According to GlobalData, industry-sponsored trials have increased from 7,721 in 2016 to 13, 685 in 2025. This growth over the …
-
Vibrent Health to join BARDA-funded clinical trial
Vibrent Health is set to join a hybrid/remote decentralised clinical research study funded by the Biomedical Advanced Research and Development …
-
Lipocine completes Phase III enrolment for LPCN 1154 in PPD
Lipocine has announced the completion of enrolment and participant dosing in its Phase III clinical trial investigating LPCN 1154, an …
-
Moderna and MSD’s cancer vaccine plus Keytruda boosts RFS in melanoma study
A combination of Moderna and MSD's personalised cancer vaccine, intismeran autogene, and MSD’s stalwart oncology drug, Keytruda (pembrolizumab), has significantly …
-
Innovations in Dermatology Trials: Embracing Digital Tools and Decentralized Approaches
Skin disease has a growing profile in drug development. New immuno-dermatology agents, topical biologics and cell-based treatments are moving through …
-
Tanabe Pharma’s dersimelagon hits success in Phase III EPP and XLP trial
Tanabe Pharma America’s oral melanocortin-1 receptor (MC1R) agonist has met the primary endpoint in a Phase III trial in patients …
-
Meta-analysis confirms nephroprotective benefits of ERAs
A recent research study, conducted by Shi and colleagues and published in the Clinical Journal of the American Society of …
-
UK DRI announces trial of blood test for Alzheimer’s diagnosis
The UK Dementia Research Institute (DRI) has announced an international research study, which is underway to assess whether a finger-prick …
-
D3 Bio receives FDA clearance to advance KRAS inhibitor trials
D3 Bio has received the US Food and Drug Administration (FDA) clearance for two investigational new drug (IND) applications, enabling …
-
2026: The time for AI to really deliver
In 2026, clinical trial design will be reshaped by artificial intelligence (AI)-powered simulation and richer clinical and real-world data. Improvements …
-
Nxera reports positive outcomes for daridorexant Phase III insomnia study
Nxera Pharma has announced positive top-line results from its Phase III study of daridorexant 50mg, aimed at treating insomnia in …
-
JPM26: Immunocore Signals Entry into Type 1 Diabetes
At the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on 14th January 2026, Immunocore outlined 2026 strategic priorities …
-
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
At the 44th Annual J.P. Morgan Healthcare Conference, Atea Pharmaceuticals outlined its strategy for hepatitis C virus (HCV), showcasing its …
